Top Markets
#1 Bedrock Bedrock +24.46%
#2 iExec RLC iExec RLC +22.99%
#3 API3 API3 +21.64%
#4 CyberDEX CyberDEX +19.33%
#5 Radicle Radicle +19.03%
#6 Talus Network Talus Network +18.92%
#7 The Bitcoin Bull The Bitcoin Bull +16.86%
#8 Orca Orca +13.08%
#9 VeThor VeThor +12.76%
#10 Nockchain Nockchain +11.65%
Coin of the day
Bedrock Bedrock
Settings
Language
ENGLISH
Currency
USD
Theme
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
Rank in Stocks #28218
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Share Price
$0.4
Last synced: 2026-10-02
Market Cap
$27.18M
Change (1 day)
-14.88%
Change (1 year)
8.11%
Country
US
Trade Cell Source, Inc. (CLCS)

Category

Healthcare
Revenue for Cell Source, Inc. (CLCS)
Revenue in Oct 2026 TTM: 0
According to Cell Source, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cell Source, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH